{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IB+Pancreatic+Cancer&page=2", "query": { "condition": "Stage IB Pancreatic Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IB+Pancreatic+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T18:08:22.039Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03410030", "title": "Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Pancreas Cancer", "Pancreatic Adenocarcinoma Resectable", "Pancreatic Ductal Adenocarcinoma", "Pancreas Metastases" ], "interventions": [ { "name": "Ascorbic Acid", "type": "DRUG" }, { "name": "Paclitaxel protein-bound", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HonorHealth Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2017-12-15", "completion_date": "2022-01-10", "has_results": false, "last_update_posted_date": "2023-04-18", "last_synced_at": "2026-06-10T18:08:22.039Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03410030" }, { "nct_id": "NCT07594626", "title": "BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Biliary Tract Carcinoma", "Metastatic Colon Carcinoma", "Metastatic Esophageal Carcinoma", "Metastatic Malignant Digestive System Neoplasm", "Metastatic Malignant Solid Neoplasm", "Metastatic Pancreatic Carcinoma", "Stage IV Colon Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "PRMT5 Inhibitor BMS-986504", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2027-12-09", "completion_date": "2030-12-09", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-06-10T18:08:22.039Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07594626" }, { "nct_id": "NCT05251038", "title": "Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Unresectable Pancreatic Cancer", "Metastatic Pancreatic Cancer", "KRAS P.G12C" ], "interventions": [ { "name": "Sotorasib", "type": "DRUG" }, { "name": "Liposomal Irinotecan (nal-IRI)", "type": "DRUG" }, { "name": "5 Fluorouracil (5FU)", "type": "DRUG" }, { "name": "Leucovorin (LV)", "type": "DRUG" }, { "name": "Gemcitabine (GEM)", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Devalingam Mahalingam", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-09-13", "completion_date": "2023-01-31", "has_results": false, "last_update_posted_date": "2023-05-11", "last_synced_at": "2026-06-10T18:08:22.039Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05251038" }, { "nct_id": "NCT04476537", "title": "RNA Precision Oncology in Advanced Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "OncoTreat", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2020-12-07", "completion_date": "2023-03-31", "has_results": true, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-06-10T18:08:22.039Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04476537" }, { "nct_id": "NCT00538850", "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Fentanyl sublingual spray", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2007-10", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2014-03-05", "last_synced_at": "2026-06-10T18:08:22.039Z", "location_count": 1, "location_summary": "Chandler, Arizona", "locations": [ { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538850" }, { "nct_id": "NCT05984602", "title": "A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 9, "start_date": "2023-07-14", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-06-10T18:08:22.039Z", "location_count": 3, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05984602" }, { "nct_id": "NCT07477418", "title": "PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma (PDAC)", "Borderline Resectable Pancreatic Cancer", "Pancreatic Neoplasms" ], "interventions": [ { "name": "Gemcitabine Delivered by Transarterial Microperfusion", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "University of Vermont", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2026-12", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-06-10T18:08:22.039Z", "location_count": 1, "location_summary": "Burlington, Vermont", "locations": [ { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT07477418" }, { "nct_id": "NCT02559674", "title": "QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "BIOLOGICAL" }, { "name": "Nab-paclitaxel", "type": "BIOLOGICAL" }, { "name": "ALT-803", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Altor BioScience", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2016-07", "completion_date": "2018-02-21", "has_results": false, "last_update_posted_date": "2020-01-27", "last_synced_at": "2026-06-10T18:08:22.039Z", "location_count": 1, "location_summary": "Honolulu, Hawaii", "locations": [ { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT02559674" }, { "nct_id": "NCT01959672", "title": "Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma", "Resectable Pancreatic Carcinoma", "Stage I Pancreatic Cancer", "Stage IA Pancreatic Cancer", "Stage IB Pancreatic Cancer", "Stage II Pancreatic Cancer", "Stage IIA Pancreatic Cancer", "Stage IIB Pancreatic Cancer", "Stage III Pancreatic Cancer" ], "interventions": [ { "name": "4-Dimensional Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Nelfinavir Mesylate", "type": "DRUG" }, { "name": "Oregovomab", "type": "BIOLOGICAL" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 11, "start_date": "2013-09-06", "completion_date": "2018-12-01", "has_results": true, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-06-10T18:08:22.039Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01959672" }, { "nct_id": "NCT03373188", "title": "VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colon Carcinoma Metastatic in the Liver", "Colorectal Adenocarcinoma", "Pancreatic Adenocarcinoma", "Resectable Pancreatic Carcinoma", "Stage I Pancreatic Cancer", "Stage IA Pancreatic Cancer", "Stage IB Pancreatic Cancer", "Stage II Pancreatic Cancer", "Stage IIA Pancreatic Cancer", "Stage IIB Pancreatic Cancer", "Stage III Pancreatic Cancer", "Stage IV Colorectal Cancer", "Stage IVA Colorectal Cancer", "Stage IVB Colorectal Cancer" ], "interventions": [ { "name": "Anti-SEMA4D Monoclonal Antibody VX15/2503", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2017-12-15", "completion_date": "2021-10-28", "has_results": false, "last_update_posted_date": "2024-03-20", "last_synced_at": "2026-06-10T18:08:22.039Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Rochester, New York", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03373188" } ] }